India's Dr Reddy's to manufacture Biosignal's furanones
Thursday, 20 January, 2005
Sydney-based Biosignal (ASX:BOS) has engaged Custom Pharmaceutical Serivces, a business unit of Indian generics-manufacturing specialist Dr Reddy's Laboratories, to develop a large-scale manufacturing procedure for Biosignal's antibacterial furanone compounds.
Dr Reddy's will then synthesise furanones for use in product development and registration Biosignal's anti-bacterial contact lenses and antifouling paints.
Custom Pharmaceutical Serivces produces cGMP compliant products in ISO certified facilities. Hyderabad-based Dr Reddy's is listed on the NYSE, and is best known for its aggressive pursuit of the generics market, launching numerous patent challenges against big pharma drugs. Its marketing rights for a generic version of Eli Lilly's Prozac ended two years ago. Dr Reddy's is also conducting research into new drugs.
Giving rotavirus vaccine at birth benefits gut bacteria
Babies who receive a RV3-BB rotavirus vaccine at birth appear to show higher levels of good...
TGA approves donanemab for treatment of early Alzheimer's
The TGA has approved the first amyloid-targeting therapy for people with Alzheimer's in...
Ultra-processed foods linked to poor health, premature death
Evidence suggests a dose-response relationship between ultra-processed food consumption and...
